ClinicalTrials.gg
CompletedNCT04354402Updated Apr 18, 2023

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

An observational study in Diffuse Large B Cell Lymphoma, sponsored by SymBio Pharmaceuticals. Completed at 17 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by SymBio Pharmaceuticals · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
25
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Lymphoma, Large B-Cell, Diffuse with a site in Japan — 7 open to participants now, 25 under way, 10 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Japan.

Started
2020
with 4 others
Observational
Only one
of the 52
Registered
27th of 52
by date
Lead sponsor
4 of 52
SymBio Pharmaceuticals

Among the 52 studies in Lymphoma, Large B-Cell, Diffuse with a site in Japan, this one is one of 5 that started in 2020, is the only observational one, and was the 27th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

7 of the 52 studies in Lymphoma, Large B-Cell, Diffuse with a site in Japan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Lymphoma, Large B-Cell, Diffuse with a site in Japan, or all of them as a file.
02

Study summary

This study is a follow-up study to update the survival time data (overall survival, progression-free survival, and duration of response) of the subjects who received SyB L-0501 at least once in Phase III Study of SyB L-0501 in combination with rituximab to treat recurrent/relapsed diffuse large B-cell lymphoma study (2017002) by reviewing their follow-up information following the study completion of Study 2017002.

In this study, the follow-up information gathered until the end of the investigation period is reviewed after obtaining informed consent from the subjects or their legal representatives. Accordingly, no intervention, such as administration of the investigational product or examination, will be performed.

Investigative methods

  1. The investigator or subinvestigator gives an explanation to a subject or his/her legal representative to obtain written informed consent to provision of information pertaining to this study.
  2. After obtaining informed consent, the investigator or subinvestigator reviews the follow-up information following the completion of Study 2017002 in source documents regarding the following items:
  1. Survival status 2. Aggravation (progression or recurrence) 3. Drugs or procedures used for treatment of DLBCL or prophylaxis against its progression or recurrence 4. Occurrence of other malignant tumors
03

Conditions studied

  • Diffuse Large B Cell Lymphoma

Keywords

  • Diffuse Large B Cell Lymphoma
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population includes subjects who received SyB L-0501 at least once in Phase III Study of SyB L-0501 in combination with rituximab to treat recurrent/relapsed diffuse large B-cell lymphoma study (2017002) and who (or their legal representatives) give informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who received the product at least once in Study 2017002
  2. Subjects who or whose legal representatives gave written to provision of data pertaining to this study

Exclusion criteria

Exclusion Criteria:

  1. Subjects whose death was confirmed during the outcome investigation period in Study 2017002
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
25 participants (actual)
Patient registry
No

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    The length of time from the date of case registration in Study 2017002 to the date of death from any cause.

    Time frame: Up to 8 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    The length of time from the date of treatment initiation (Day 1) in the first cycle in Study 2017002 to the date of progression (including recurrence/relapse), death from any cause, or censoring.

    Time frame: Up to 8 months

  2. Duration of Response (DOR)

    The length of time from the date when complete response (CR) or partial response (PR) was achieved in Study 2017002 to the date of progression (including recurrence/relapse), death from any cause, or censoring.

    Time frame: Up to 8 months

07

Study locations

17 sites
  • Research Site
    Nagoya, Aichi, Japan
  • Research Site
    Matsuyama, Ehime, Japan
  • Research Site
    Ota, Gunma, Japan
  • Research Site
    Fukuyama, Hiroshima, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Osakasayama, Osaka, Japan
  • Research Site
    Izumo, Shimane, Japan
  • Research Site
    Chuo-ku, Tokyo, Japan
  • Research Site
    Koto, Tokyo, Japan
  • Research Site
    Shinagawa-ku, Tokyo, Japan
  • Research Site
    Akita, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Ibaraki, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Nagasaki, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Yamagata, Japan
08

References and documents

Publications

  • Murayama K, Kiguchi T, Izutsu K, Kameoka Y, Hidaka M, Kato H, Rai S, Kuroda J, Ishizawa K, Ichikawa S, Ando K, Ogura M, Fukushima K, Terui Y. Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma. Ann Hematol. 2022 May;101(5):979-989. doi: 10.1007/s00277-022-04801-2. Epub 2022 Mar 4. PubMed 35244756 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Nov 2020, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2020
First posted
Apr 21, 2020
StartActual
Mar 26, 2020
Primary completionActual
Nov 11, 2020
CompletionActual
Nov 11, 2020
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04354402
Responsible party
Sponsor
First posted
Apr 21, 2020
Start date
Mar 26, 2020
Primary completion
Nov 11, 2020
Completion
Nov 11, 2020
Last update
Apr 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion